TNSN07147A1 - Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women - Google Patents

Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women

Info

Publication number
TNSN07147A1
TNSN07147A1 TNP2007000147A TNSN07147A TNSN07147A1 TN SN07147 A1 TNSN07147 A1 TN SN07147A1 TN P2007000147 A TNP2007000147 A TN P2007000147A TN SN07147 A TNSN07147 A TN SN07147A TN SN07147 A1 TNSN07147 A1 TN SN07147A1
Authority
TN
Tunisia
Prior art keywords
receptor modulator
estrogen receptor
sexual dysfunction
sex steroid
selective estrogen
Prior art date
Application number
TNP2007000147A
Other languages
English (en)
Inventor
Mohamed El-Alfy
Fernand Labrie
Louise Berger
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of TNSN07147A1 publication Critical patent/TNSN07147A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TNP2007000147A 2004-10-20 2007-04-19 Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women TNSN07147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62045204P 2004-10-20 2004-10-20
PCT/CA2005/001612 WO2006042409A1 (fr) 2004-10-20 2005-10-20 Precurseurs de steroide sexuel, seuls ou combines a un modulateur de recepteur d'oestrogene selectif et/ou a des oestrogenes et/ou a un inhibiteur de phosphodiesterase de type 5 cgmp, pour prevenir et traiter la secheresse vaginale et les dysfonctionnements sexuels chez la femme postmenopausee

Publications (1)

Publication Number Publication Date
TNSN07147A1 true TNSN07147A1 (fr) 2008-11-21

Family

ID=36202646

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000147A TNSN07147A1 (fr) 2004-10-20 2007-04-19 Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women

Country Status (27)

Country Link
US (3) US8835413B2 (fr)
EP (1) EP1802312B1 (fr)
JP (3) JP5057983B2 (fr)
KR (1) KR20070067235A (fr)
CN (5) CN106138065A (fr)
AP (1) AP2365A (fr)
AU (1) AU2005297367B2 (fr)
BR (1) BRPI0516243C1 (fr)
CA (2) CA2584524C (fr)
DK (1) DK1802312T3 (fr)
EA (1) EA014878B1 (fr)
ES (1) ES2553101T3 (fr)
GE (1) GEP20105066B (fr)
HK (1) HK1225629A1 (fr)
HR (1) HRP20070169B1 (fr)
HU (1) HUE025651T2 (fr)
IL (3) IL182633A (fr)
MA (1) MA29018B1 (fr)
MX (3) MX2007004830A (fr)
NO (1) NO340123B1 (fr)
NZ (1) NZ554619A (fr)
RS (1) RS20070166A (fr)
SG (2) SG10201404796QA (fr)
TN (1) TNSN07147A1 (fr)
UA (1) UA93985C2 (fr)
WO (1) WO2006042409A1 (fr)
ZA (1) ZA200703198B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AP2365A (en) * 2004-10-20 2012-02-20 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women.
KR20090029237A (ko) * 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
US20080312239A1 (en) 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
EP2011496A1 (fr) * 2007-07-03 2009-01-07 Indena S.P.A. Combinaisons de substances vasoactives avec des estrogènes et leur utilisation dans le traitement de dysfonctionnements sexuels chez les femmes
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US20130231317A1 (en) * 2011-07-19 2013-09-05 Michael S. Riepl Dhea bioadhesive controlled release gel
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
CA2857057A1 (fr) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Modulateurs fluores des recepteurs d'ƒstrogenes et leurs utilisations
CA2857061A1 (fr) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Nouveaux composes benzopyranes, compositions et utilisations de ceux-ci
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2017100378A2 (fr) * 2015-12-07 2017-06-15 Therapeuticsmd, Inc. Compositions pharmaceutiques à base d'œstradiol introduites par voie vaginale et procédés associés
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2018071437A1 (fr) * 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Traitement au lasofoxifène de l'atrophie vulvovaginale (wa) et de l'ostéoporose chez des survivantes du cancer du sein ou d'autres malignités
KR102623130B1 (ko) 2016-10-11 2024-01-10 듀크 유니버시티 Er+ 유방암의 라소폭시펜 치료
RU2636619C1 (ru) * 2017-02-20 2017-11-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения вагинальной атрофии у женщин в постменопаузе с учетом состояния эпителия и микробиоценоза влагалища
WO2019199891A1 (fr) 2018-04-10 2019-10-17 Duke University Traitement du cancer du sein avec du lasofoxifène
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11690852B2 (en) 2020-12-01 2023-07-04 Endorecherche. Inc. Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor
CN117924262A (zh) * 2022-10-14 2024-04-26 中国科学院上海药物研究所 二氢苯并噻喃类衍生物及其制备方法和用途

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104924A (ja) 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5246704A (en) 1989-01-23 1993-09-21 Kanebo, Ltd. Vaginal suppository
AU5281990A (en) 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
ES2222633T3 (es) 1989-07-07 2005-02-01 Endorecherche Inc. Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna.
CA2062792C (fr) 1989-07-07 2006-03-21 Fernard Labrie Traitement des maladies liees aux androgenes
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
HU228385B1 (en) * 1993-01-19 2013-03-28 Endorech Inc Use of dehydroepiandrosterone for the preparation of a medicament for the treatment of sexual disordes
JP2698865B2 (ja) 1994-08-08 1998-01-19 仲昭 大澤 筋緊張性ジストロフィー症治療剤
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
PL327831A1 (en) 1996-01-11 1999-01-04 Novo Nordisk As Application of 3,4-diphenylchromanes in production of a pharmaceutic agent for treating or preventing menopause symptoms
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
IL124881A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
ES2162198T3 (es) 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
JP2001520999A (ja) 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
EP1083904A2 (fr) * 1998-06-11 2001-03-21 Endorecherche Inc. Compositions pharmaceutiques et utilisations pour l'androst-5-ene-3 beta,17 beta-diol
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US20030181353A1 (en) 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
TWI281398B (en) 1999-06-11 2007-05-21 Watson Pharmaceuticals Inc Administration of non-oral androgenic steroids to women
US7452545B2 (en) 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US20070042060A1 (en) 1999-07-01 2007-02-22 Thompson Ronald J Methods to treat one or all of the defined etiologies of female sexual Dysfunction
US20050245494A1 (en) 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20020165429A1 (en) 1999-07-01 2002-11-07 40 J's Llc Clitoral sensitizing arrangements
EP1196163B1 (fr) 1999-07-06 2009-11-11 Endorecherche Inc. Compositions pharmaceutiques pour le traitement de la resistance a l'insuline
EP1251855A1 (fr) 2000-01-28 2002-10-30 Endorecherche, Inc. Modulateurs selectifs du recepteur d'oestrogene, en combinaison avec des oestrogenes
US6614831B2 (en) * 2000-02-10 2003-09-02 Process Technology International, Inc. Mounting arrangement for auxiliary burner or lance
CN1315718A (zh) * 2000-03-24 2001-10-03 周广胜 一种中字格对称习字法
US20020022052A1 (en) 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
JP2002024098A (ja) * 2000-07-04 2002-01-25 Canon Inc 情報処理装置、情報処理システム、情報処理方法及び記録媒体
EP1356438B1 (fr) * 2000-07-10 2014-06-18 PayPal, Inc. Systeme et procede de verification d'un instrument financier
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20040092583A1 (en) 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
WO2002069906A2 (fr) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Composes et procedes pour le traitement de desordres urogenitaux
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
WO2002085296A2 (fr) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, et formulations de traitement de maladies respiratoires et pulmonaires a l'aide de steroides non-glucocorticoides et/ou d'ubiquinone et d'un agent broncho-dilatateur
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
JP3533664B2 (ja) * 2001-06-27 2004-05-31 ソニー株式会社 負極材料およびそれを用いた電池
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
FR2828100B1 (fr) 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7348352B2 (en) 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
EP1492486A2 (fr) 2002-04-10 2005-01-05 Ruey J. Dr. Yu Compositions d'uree
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1704161A4 (fr) 2004-01-07 2011-06-08 Endorech Inc Produits pharmaceutiques steroidiens diriges sur l'helice 12
US20050181057A1 (en) 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20060276442A1 (en) 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US20080119445A1 (en) 2004-09-08 2008-05-22 Woodward John R Methods of female sexual enhancement
US20060252734A1 (en) 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
AP2365A (en) 2004-10-20 2012-02-20 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women.
BRPI0517950A (pt) 2004-11-01 2008-10-21 Endorech Inc uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele
CA2612380C (fr) 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Compositions oestrogeniques pour administration vaginale
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
JP4179624B2 (ja) 2006-07-18 2008-11-12 ヒロセ電機株式会社 平型導体用電気コネクタ
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP5373931B2 (ja) * 2012-03-22 2013-12-18 日本電信電話株式会社 仮想視点画像生成方法，仮想視点画像生成装置および仮想視点画像生成プログラム

Also Published As

Publication number Publication date
ZA200703198B (en) 2008-09-25
NZ554619A (en) 2011-01-28
IL246698B (en) 2021-07-29
CA2749235A1 (fr) 2006-04-27
MX2019007772A (es) 2019-09-09
HUE025651T2 (en) 2016-04-28
BRPI0516243B1 (pt) 2020-08-11
JP2012162579A (ja) 2012-08-30
JP5057983B2 (ja) 2012-10-24
NO20072518L (no) 2007-07-19
US20070270394A1 (en) 2007-11-22
WO2006042409A1 (fr) 2006-04-27
IL182633A (en) 2017-01-31
US10076525B2 (en) 2018-09-18
BRPI0516243A (pt) 2008-08-26
IL182633A0 (en) 2007-09-20
CA2584524C (fr) 2012-02-07
BRPI0516243B8 (pt) 2021-02-23
KR20070067235A (ko) 2007-06-27
CN101106999A (zh) 2008-01-16
ES2553101T3 (es) 2015-12-04
EP1802312B1 (fr) 2015-09-16
MX2007004830A (es) 2007-10-04
CA2584524A1 (fr) 2006-04-27
SG155258A1 (en) 2009-09-30
RS20070166A (en) 2008-09-29
EA200700893A1 (ru) 2007-10-26
BRPI0516243C1 (pt) 2021-05-25
CN102357248A (zh) 2012-02-22
GEP20105066B (en) 2010-08-25
CN102406650A (zh) 2012-04-11
JP2012162578A (ja) 2012-08-30
AU2005297367A1 (en) 2006-04-27
DK1802312T3 (en) 2015-12-14
HRP20070169A2 (en) 2007-09-30
US10478443B2 (en) 2019-11-19
UA93985C2 (ru) 2011-03-25
HK1225629A1 (zh) 2017-09-15
CN101106999B (zh) 2017-06-09
IL246698A0 (en) 2016-08-31
NO340123B1 (no) 2017-03-13
AP2365A (en) 2012-02-20
EP1802312A1 (fr) 2007-07-04
JP5653965B2 (ja) 2015-01-14
CN106138065A (zh) 2016-11-23
AU2005297367B2 (en) 2010-02-04
EP1802312A4 (fr) 2009-02-18
HRP20070169B1 (hr) 2020-07-10
US20180271880A1 (en) 2018-09-27
CN106038572A (zh) 2016-10-26
SG10201404796QA (en) 2014-10-30
IL249633B (en) 2019-06-30
CA2749235C (fr) 2014-08-12
AP2007003970A0 (en) 2007-04-30
JP2008516995A (ja) 2008-05-22
US20160058774A1 (en) 2016-03-03
MA29018B1 (fr) 2007-11-01
MX368189B (es) 2019-09-23
US8835413B2 (en) 2014-09-16
EA014878B1 (ru) 2011-02-28
IL249633A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
TNSN07147A1 (fr) Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
EP0462189B1 (fr) Therapie combinee pour le traitement de maladies sensibles a l'oestrogene
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
Pearson et al. Antiestrogen treatment of breast cancer: an overview
US20140080794A1 (en) Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders
WO2003017973A1 (fr) Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
EE05344B1 (et) Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel
RU2003105159A (ru) Способ лечения климактерических расстройств у женщин во время или после менопаузы
CA2448278A1 (fr) Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
CA2291160C (fr) Therapie combinatoire permettant de moduler la reponse sexuelle chez un patient
CA2605796A1 (fr) Compositions pharmaceutiques et methodes comprenant une combinaison d'un modulateur selectif du recepteur de l'oestrogene et d'un inhibiteur de l'aromatase
RU2006125417A (ru) Производные 1-n-фениламино-1н-имидазола и содержащие их фармацевтические композиции
RU2003112974A (ru) Комбинированная терапия для лечения эстрогенчувствительных заболеваний
JP2007506780A5 (fr)
KR20080056719A (ko) 9,11-디하이드로코르텍솔론 Ｃ3-Ｃ10 17α-에스테르의항-성선 자극 호르몬제로서의 용도
Sorbera et al. Pipendoxifene
RU2010115647A (ru) Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей
US20030207891A1 (en) Combination therapy for modulating the human sexual response
Coutinho Vaginal pills: systemic contraception induced by vaginal administration of contraceptive pills
RU2008112142A (ru) Терапевтическое средство для лечения гипертензии
EP2266567A1 (fr) Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel